Healthcare company DexCom, Inc. (NASDAQ: DXCM) announced preliminary results for the fourth quarter of 2023, reporting an estimated double-digit increase in revenues.
- Fourth-quarter revenue, unaudited, is expected to be at least $1.03 billion, which represents an increase of 26% over the same period of 2022
- US revenue is expected to be around $765 million in the December quarter, which is up 26% over the fourth quarter of the prior year
- At $265 million, international revenue is estimated to be higher by 27% from the prior-year quarter
- Stelo, the company’s new glucose sensor for people with type-2 diabetes who do not use insulin, has been submitted to the FDA for review
- For FY24, the company expects revenues of $4.15-4.35 billion, representing expected organic growth of 16-21% Year-over-year
- Full-year adjusted gross profit margin is expected to be approximately 63 – 64%
- The management is looking for an adjusted operating margin of around 20% for fiscal 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
INTC Stock: Where does Intel stand in the semiconductor race?
Intel Corporation (NASDAQ: INTC) is working to regain dominance in the semiconductor market, while evolving from an integrated chipmaker into a global foundry player. The turnaround plan involves massive capital
J.M. Smucker (SJM) is prioritizing brands with the highest growth potential, a few points to note
Shares of The J.M. Smucker Co. (NYSE: SJM) dipped over 1% on Monday. The stock has dropped 13% over the past 12 months. The branded foods seller is operating in
Foxconn Technology reports a 22% surge in Q4 2025 revenue
Foxconn Technology Group, a key supplier for Apple Inc. (AAPL), announced financial results for the fourth quarter of fiscal 2025. Hon Hai Precision Industry Co., Foxconn's parent, said Q4 revenues increased
